IOVA (Iovance Biotherapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IOVA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Raj K. Puri | Chief Regulatory Officer | MIXED | — | — |
| 2026-09-03 | IGOR BILINSKY | Chief Operating Officer | MIXED | — | — |
| 2026-09-03 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | — | — |
| 2026-08-12 | Daniel Gordon Kirby | Chief Commercial Officer | MIXED | — | — |
| 2026-08-10 | Corleen M. Roche | Chief Financial Officer | MIXED | — | — |
| 2026-06-18 | Raj K. Puri | Chief Regulatory Officer | A | — | — |
| 2026-06-18 | Ryan D Maynard | Director | A | — | — |
| 2026-06-18 | Athena Countouriotis | Director | A | — | — |
| 2026-06-18 | Iain D. Dukes | Director | A | — | — |
| 2026-06-18 | MICHAEL WEISER | Director | A | — | — |
| 2026-06-09 | FINCKENSTEIN FRIEDRICH GRAF | Chief Medical Officer | MIXED | — | — |
| 2026-06-09 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | — | — |
| 2026-06-09 | Raj K. Puri | Chief Regulatory Officer | MIXED | — | — |
| 2026-06-09 | IGOR BILINSKY | Chief Operating Officer | MIXED | — | — |
| 2026-06-03 | Raj K. Puri | Chief Regulatory Officer | MIXED | — | — |
| 2026-06-03 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | — | — |
| 2026-06-03 | FINCKENSTEIN FRIEDRICH GRAF | Chief Medical Officer | MIXED | — | — |
| 2026-06-03 | IGOR BILINSKY | Chief Operating Officer | MIXED | — | — |
| 2026-05-13 | Daniel Gordon Kirby | Chief Commercial Officer | MIXED | — | — |
| 2026-03-11 | Frederick G Vogt | Interim CEO & General Counsel | A | — | — |
| 2026-03-11 | FINCKENSTEIN FRIEDRICH GRAF | Chief Medical Officer | A | — | — |
| 2026-03-11 | Raj K. Puri | Chief Regulatory Officer | A | — | — |
| 2026-03-11 | IGOR BILINSKY | Chief Operating Officer | A | — | — |
| 2026-03-11 | Daniel Gordon Kirby | Chief Commercial Officer | A | — | — |
| 2026-03-11 | Corleen M. Roche | Chief Financial Officer | A | — | — |
| 2026-03-06 | FINCKENSTEIN FRIEDRICH GRAF | Chief Medical Officer | MIXED | — | — |
| 2026-03-06 | IGOR BILINSKY | Chief Operating Officer | MIXED | — | — |
| 2026-03-06 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | — | — |
| 2026-03-06 | Raj K. Puri | Chief Regulatory Officer | MIXED | — | — |
| 2026-03-04 | Raj K. Puri | Chief Regulatory Officer | MIXED | — | — |
| 2026-03-04 | IGOR BILINSKY | Chief Operating Officer | MIXED | — | — |
| 2026-03-04 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | — | — |
| 2026-03-04 | FINCKENSTEIN FRIEDRICH GRAF | Chief Medical Officer | MIXED | — | — |
| 2026-02-26 | Daniel Gordon Kirby | Chief Commercial Officer | MIXED | — | — |
| 2026-02-12 | Daniel Gordon Kirby | Chief Commercial Officer | MIXED | — | — |
| 2025-12-03 | Raj K. Puri | Chief Regulatory Officer | MIXED | — | — |
| 2025-12-03 | IGOR BILINSKY | Chief Operating Officer | MIXED | — | — |
| 2025-12-03 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | — | — |
| 2025-12-03 | FINCKENSTEIN FRIEDRICH GRAF | Chief Medical Officer | MIXED | — | — |
| 2025-09-04 | Raj K. Puri | Chief Regulatory Officer | MIXED | — | — |
| 2025-09-04 | IGOR BILINSKY | Chief Operating Officer | MIXED | — | — |
| 2025-09-04 | Frederick G Vogt | Interim CEO & General Counsel | MIXED | — | — |
| 2025-09-04 | FINCKENSTEIN FRIEDRICH GRAF | Chief Medical Officer | MIXED | — | — |
| 2025-08-08 | Corleen M. Roche | Chief Financial Officer | A | — | — |
| 2025-06-17 | WENDY L YARNO | Director | A | — | — |
| 2025-06-17 | MICHAEL WEISER | Director | A | — | — |
| 2025-06-17 | Iain D. Dukes | Director | A | — | — |
| 2025-06-17 | Athena Countouriotis | Director | A | — | — |
| 2025-06-17 | Ryan D Maynard | Director | A | — | — |
| 2025-06-06 | Daniel Gordon Kirby | Chief Commercial Officer | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 28,067,333 | — |
| — | Interim CEO & General Counsel | 586,459 | — |
| — | Director | 568,783 | — |
| — | President and CEO | 298,786 | — |
| — | Chief Regulatory Officer | 253,584 | — |
| — | Chief Commercial Officer | 154,511 | — |
| — | Director | 141,116 | — |
| — | Chief Medical Officer | 140,111 | — |
| — | Chief Operating Officer | 138,237 | — |
| — | Chief Financial Officer | 64,993 | — |
| — | Director | 54,000 | — |
| — | Chief Financial Officer | 49,995 | — |
| — | Director | 7,500 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IOVA quote page; the site-wide leaderboard is on the insider transactions hub.